Related Experiment Video
Updated: Jun 6, 2026
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
[Malignant gliomas]
S Haberer1, A Assouline, J-J Mazeron
1Service d'oncologie radiothérapique, centre des tumeurs, groupe hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
Abstract:
Glial tumors represent 2000 to 3000 new cases per year in France and 75% of them are of high grade. Recent understanding of the molecular biology of these tumors revealed the importance of 1p19q codeletion and mgMT promotor methylation. Radiotherapy also recently evolved with the progress in medical imaging which allows a better definition of the target volumes. Even modest, therapeutic progress is based on chemoradiotherapy with temozolomide and on the development of non-coplanar conformational radiotherapy. Knowledge and precise evaluation of potential late effects of our treatments is necessary due to actual improvement of survival with chemoradiotherapy in glioblastoma.
Insights
High-grade glial tumors are common, with molecular markers like 1p19q codeletion and MGMT promoter methylation guiding treatment. Advances in radiotherapy and chemoradiotherapy improve survival, necessitating evaluation of late treatment effects.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Molecular Oncology
Background:
- Glial tumors account for 2000-3000 annual cases in France, with 75% being high-grade.
- Molecular insights, including 1p19q codeletion and MGMT promoter methylation, are crucial for understanding glial tumors.
- Recent advancements in medical imaging enhance target volume definition in radiotherapy.
Purpose of the Study:
- To summarize current understanding of glial tumor treatment.
- To highlight the role of molecular markers and advanced radiotherapy techniques.
- To emphasize the need for evaluating late treatment effects due to improved survival.
Main Methods:
- Review of recent molecular biology findings in glial tumors.
- Discussion of advancements in radiotherapy, including non-coplanar conformational radiotherapy.
- Focus on chemoradiotherapy with temozolomide as a standard treatment.
Main Results:
- 1p19q codeletion and MGMT promoter methylation are key molecular indicators.
- Chemoradiotherapy with temozolomide and advanced radiotherapy techniques represent therapeutic progress.
- Improved survival rates in glioblastoma patients treated with chemoradiotherapy.
Conclusions:
- Understanding molecular markers is essential for personalized glial tumor treatment.
- Advances in radiotherapy and chemoradiotherapy are improving patient outcomes.
- Further research is needed to assess and manage potential late effects of these treatments.
